Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultra-rare disease therapies, has announced the grant of 45,292 restricted stock units (RSUs) to 29 newly hired non-executive officers. The grants were approved by the company's compensation committee and issued under the Ultragenyx Employment Inducement Plan on July 16, 2025.
The RSUs will vest over a four-year period, with 25% of the shares vesting annually on each grant date anniversary, contingent on continued employment.
Ultragenyx Pharmaceutical (NASDAQ: RARE), un'azienda biofarmaceutica specializzata in terapie per malattie rare e ultra-rare, ha annunciato la concessione di 45.292 unità azionarie vincolate (RSU) a 29 nuovi dirigenti non esecutivi. Le assegnazioni sono state approvate dal comitato per la remunerazione della società e sono state emesse nell'ambito del Piano di Incentivazione all'Assunzione di Ultragenyx il 16 luglio 2025.
Le RSU matureranno in un periodo di quattro anni, con il 25% delle azioni che matureranno ogni anno nell'anniversario della data di assegnazione, a condizione che l'impiego continui.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una compañía biofarmacéutica especializada en terapias para enfermedades raras y ultra-raras, ha anunciado la concesión de 45,292 unidades restringidas de acciones (RSUs) a 29 nuevos oficiales no ejecutivos. Las concesiones fueron aprobadas por el comité de compensación de la empresa y emitidas bajo el Plan de Incentivos de Empleo de Ultragenyx el 16 de julio de 2025.
Las RSUs se consolidarán en un período de cuatro años, con el 25% de las acciones consolidándose anualmente en cada aniversario de la fecha de concesión, condicionado a la continuidad del empleo.
Ultragenyx Pharmaceutical (NASDAQ: RARE)는 희귀 및 초희귀 질환 치료제를 전문으로 하는 생명공학 제약회사로, 29명의 신규 비임원 임원에게 45,292개의 제한 주식 단위(RSUs)를 부여했다고 발표했습니다. 이 부여는 회사의 보상위원회에서 승인되었으며, 2025년 7월 16일 Ultragenyx 고용 유인 계획에 따라 발행되었습니다.
RSU는 4년 기간에 걸쳐 점진적으로 취득되며, 매년 부여일 기념일에 25%의 주식이 취득 조건인 계속 고용 상태 하에 취득됩니다.
Ultragenyx Pharmaceutical (NASDAQ : RARE), une société biopharmaceutique spécialisée dans les thérapies pour maladies rares et ultra-rares, a annoncé l'attribution de 45 292 unités d'actions restreintes (RSU) à 29 nouveaux cadres non exécutifs. Ces attributions ont été approuvées par le comité de rémunération de la société et émises dans le cadre du Plan d'Incitation à l'Emploi d'Ultragenyx le 16 juillet 2025.
Les RSU seront acquises sur une période de quatre ans, avec 25 % des actions acquises chaque année à la date anniversaire de l'attribution, sous réserve de la poursuite de l'emploi.
Ultragenyx Pharmaceutical (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene und ultra-seltene Krankheiten spezialisiert hat, hat die Gewährung von 45.292 Restricted Stock Units (RSUs) an 29 neu eingestellte nicht geschäftsführende Führungskräfte bekannt gegeben. Die Zuteilungen wurden vom Vergütungsausschuss des Unternehmens genehmigt und am 16. Juli 2025 im Rahmen des Ultragenyx Employment Inducement Plans ausgegeben.
Die RSUs werden über einen Zeitraum von vier Jahren vesten, wobei jährlich jeweils 25 % der Aktien am Jahrestag des jeweiligen Zuteilungsdatums unter der Voraussetzung einer fortgesetzten Anstellung vesten.
- None.
- None.
NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,292 restricted stock units of the company’s common stock to 29 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
What type of stock compensation did Ultragenyx (RARE) grant to new employees in July 2025?
What is the vesting schedule for Ultragenyx's July 2025 RSU grants?
How many new employees received RSUs from Ultragenyx in July 2025?
Under which Nasdaq rule were Ultragenyx's July 2025 RSU grants made?
